Flutemetamol F 18 Injection Formulation Comparison
NCT07873463
This study is recruiting at 5 US sites in 2 states, according to its ClinicalTrials.gov record last updated .
Summary
VIZAMYL (flutemetamol F 18 injection) is a drug used during Positron Emission Tomography (PET) brain scans. It helps doctors detect the presence of amyloid protein, which is associated with Alzheimer's disease and other conditions affecting memory or thinking. A new formulation of this drug, called GE-287, has been developed. This new formulation may offer advantages for patient tolerability and can be produced more reliably and efficiently.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Cognitive Dysfunction
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 50 to 110 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- GE Healthcare
- Last updated on ClinicalTrials.gov
- November 5, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Florida · 4
- Visionary Investigator Network · Aventura, FL
- Visionary Investigator Network · Miami, FL
- Visionary Investigator Network · Miami, FL
- Clinical Site Partners, LLC dba Flourish Research · Winter Park, FL
Georgia · 1
- Center for Advanced Research & Education LLC dba Flourish Research Gainesville · Gainesville, GA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.